Harris aims to broaden some IRA provisions, including Medicare’s power to negotiate drug prices, while Trump has publicly endorsed a more industry-friendly approach.

Data Validation and Compliance: The Sapio LIMS and ELN ensure adherence to the FDA and EMA-guided IGX assay validation approach, providing for monitoring and reporting on cut points, sensitivity, ...

Alimentiv, a full-service GI CRO and pioneer in IBD medical imaging solutions since 1986, is excited to announce the expansion of its partnership with Satisfai Health, a leader in AI medical solutions ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

In a breakthrough for cancer research, Medgnosis has leveraged its state-of-the-art generative AI (GenAI) system to transform drug discovery. This GenAI targets both druggable and undruggable proteins ...

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney.

The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.